BENITEC BIOPHARMA INC (BNTC) Stock Price, Quote, News and Overview
NASDAQ:BNTC - Nasdaq - US08205P2092 - Common Stock - Currency: USD
BNTC Quote, Performance and Key Statistics
NASDAQ:BNTC (8/1/2025, 2:49:27 PM)
11.03
+0.1 (+0.91%)
The current stock price of BNTC is 11.03 USD. In the past month the price decreased by -14.21%. In the past year, price increased by 36.45%.
BNTC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.52 | 346.36B | ||
| AMGN | AMGEN INC | 14.33 | 159.93B | ||
| GILD | GILEAD SCIENCES INC | 14.66 | 141.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 119.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 59.05B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 51.76B | ||
| ARGX | ARGENX SE - ADR | 72.55 | 41.16B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.59 | 32.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.72B | ||
| INSM | INSMED INC | N/A | 20.41B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 8.12 | 19.05B |
Related stock screener links
About BNTC
Company Profile
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 16 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Company Info
BENITEC BIOPHARMA INC
3940 Trust Way
Hayward CALIFORNIA 94545 US
CEO: Jerel Banks
Employees: 16
Phone: 15107800819
BENITEC BIOPHARMA INC / BNTC FAQ
What is the stock price of BENITEC BIOPHARMA INC today?
The current stock price of BNTC is 11.03 USD. The price increased by 0.91% in the last trading session.
What is the ticker symbol for BENITEC BIOPHARMA INC stock?
The exchange symbol of BENITEC BIOPHARMA INC is BNTC and it is listed on the Nasdaq exchange.
On which exchange is BNTC stock listed?
BNTC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BENITEC BIOPHARMA INC stock?
13 analysts have analysed BNTC and the average price target is 26.23 USD. This implies a price increase of 137.79% is expected in the next year compared to the current price of 11.03. Check the BENITEC BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BENITEC BIOPHARMA INC worth?
BENITEC BIOPHARMA INC (BNTC) has a market capitalization of 289.54M USD. This makes BNTC a Micro Cap stock.
How many employees does BENITEC BIOPHARMA INC have?
BENITEC BIOPHARMA INC (BNTC) currently has 16 employees.
What are the support and resistance levels for BENITEC BIOPHARMA INC (BNTC) stock?
BENITEC BIOPHARMA INC (BNTC) has a support level at 10.92 and a resistance level at 11.03. Check the full technical report for a detailed analysis of BNTC support and resistance levels.
Should I buy BENITEC BIOPHARMA INC (BNTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BNTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BNTC, evaluating the profitability, health, valuation and growth aspects
- BENITEC BIOPHARMA INC (BNTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BENITEC BIOPHARMA INC (BNTC) Sales and EPS estimates to see what analysts future expectations are.
- BENITEC BIOPHARMA INC (BNTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BENITEC BIOPHARMA INC (BNTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BENITEC BIOPHARMA INC (BNTC) Stock Chart to make your own analysis
- BENITEC BIOPHARMA INC (BNTC) Latest news and press-releases to stay up to date.
Does BENITEC BIOPHARMA INC (BNTC) stock pay dividends?
BNTC does not pay a dividend.
When does BENITEC BIOPHARMA INC (BNTC) report earnings?
BENITEC BIOPHARMA INC (BNTC) will report earnings on 2025-09-24, after the market close.
What is the Price/Earnings (PE) ratio of BENITEC BIOPHARMA INC (BNTC)?
BENITEC BIOPHARMA INC (BNTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.37).
What is the Short Interest ratio of BENITEC BIOPHARMA INC (BNTC) stock?
The outstanding short interest for BENITEC BIOPHARMA INC (BNTC) is 5.67% of its float. Check the ownership tab for more information on the BNTC short interest.
BNTC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BNTC. When comparing the yearly performance of all stocks, BNTC turns out to be only a medium performer in the overall market: it outperformed 51.95% of all stocks.
BNTC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BNTC. No worries on liquidiy or solvency for BNTC as it has an excellent financial health rating, but there are worries on the profitability.
BNTC Financial Highlights
Over the last trailing twelve months BNTC reported a non-GAAP Earnings per Share(EPS) of -2.37. The EPS increased by 76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.77% | ||
| ROE | -27.78% | ||
| Debt/Equity | 0 |
BNTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to BNTC. The Buy consensus is the average rating of analysts ratings from 13 analysts.